Base de dados : LILACS
Pesquisa : D02.078.370.380 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-419156
Autor: Xiong, G. S; Wu, S. M; Zhang, X. W; Ge, Z. Z.
Título: Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;39(1):85-90, Jan. 2006. tab.
Idioma: en.
Resumo: The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain. Patients scheduled for ERCP were randomized into two groups in a double-blind manner: the patients in the gabexate group were treated with continuous intravenous infusion of 300 mg gabexate dissolved in 500 mL Ringer's solution at 111 mL/h, starting 30 min before the endoscopic maneuvers and continuing up to 4 h after them; placebo group patients were treated only with Ringer's solution also starting 30 min before the endoscopic maneuvers and continuing up to 4 h. Data for 193 patients were analyzed. The incidence of post-ERCP pancreatitis was 3 patients (3.1 percent) in the gabexate group and 10 (10.5 percent) in the placebo group (P = 0.040). The incidence of hyperamylasemia was 33 patients (33.7 percent) in the gabexate group and 42 (43.7 percent) in the placebo group (P = 0.133). The incidence of pancreatic pain was 15 patients (15.3 percent) in the gabexate group and 28 (29.5 percent) in the placebo group (P = 0.018). The results suggest that a 4.5-h infusion of gabexate (for a total of 300 mg) could prevent post-ERCP pancreatitis and pancreatic pain.
Descritores: Dor Abdominal/prevenção & controle
Colangiopancreatografia Retrógrada Endoscópica/efeitos adversos
Gabexato/administração & dosagem
Hiperamilassemia/prevenção & controle
Pancreatite/prevenção & controle
Inibidores de Serino Proteinase/administração & dosagem
-Doença Aguda
Dor Abdominal/etiologia
Colangiopancreatografia Retrógrada Endoscópica/métodos
Método Duplo-Cego
Hiperamilassemia/etiologia
Estudos Prospectivos
Pancreatite/etiologia
Limites: Humanos
Masculino
Feminino
Responsável: BR1.1 - BIREME


  2 / 2 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Id: lil-277245
Autor: Valderrama Labarca, Rodrigo.
Título: Nuevas posibilidades farmacológicas en pancreatitis aguda / New pharmacological advances and strategies in acute pancreatitis
Fonte: Gastroenterol. latinoam;11(2):225-31, jul. 2000. tab.
Idioma: es.
Conferência: Apresentado em: Curso de Avances en Gastroenterología: Farmacoterapia en Gastroenterología; 21, Santiago de Chile, 27-28 jul. 2000.
Descritores: Pancreatite/tratamento farmacológico
-Anti-Inflamatórios/uso terapêutico
Antibacterianos/uso terapêutico
Gabexato/farmacocinética
Octreotida/farmacocinética
Somatostatina/farmacocinética
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde